Danaher's Leica Biosystems to Acquire StatLab Medical Products
DHR sits 24% above its 52-week low of $160.93.
Summary
Danaher's Leica Biosystems is acquiring StatLab Medical Products, a developer of anatomical pathology products, from private equity sellers. The deal expands Leica's cancer diagnostics and digital pathology capabilities, with the president citing AI-enabled diagnostics as a key driver. Terms were not disclosed, but the transaction is expected to close by end of 2026. This follows Danaher's recent $9.9B Masimo acquisition and a series of large debt financings, signaling continued M&A appetite in life sciences. The undisclosed price makes the financial impact unclear, but the strategic fit in Danaher's diagnostics portfolio is evident.
At the time of this announcement, DHR was trading at $199.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $140.9B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.